Hostname: page-component-8448b6f56d-gtxcr Total loading time: 0 Render date: 2024-04-18T01:30:56.467Z Has data issue: false hasContentIssue false
  • English
  • Français

Varicella Vaccination for Healthcare Workers at a University Hospital An Analysis of Costs and Benefits

Published online by Cambridge University Press:  02 January 2015

Alan M. Tennenberg ,
Juanita E. Brassard ,
Jaclyn Van Lieu  and
Lewis M. Drusin
Alan M. Tennenberg*
Affiliation:
Department of Epidemiology, Department of Medicine, Cornell University Medical College, New York City, New York The New York Hospital, the Department of Public Health, Department of Medicine, Cornell University Medical College, New York City, New York Division of International Medicine and Infectious Diseases, Department of Medicine, Cornell University Medical College, New York City, New York
Juanita E. Brassard
Affiliation:
Occupational Health Service, Department of Medicine, Cornell University Medical College, New York City, New York
Jaclyn Van Lieu
Affiliation:
Occupational Health Service, Department of Medicine, Cornell University Medical College, New York City, New York
Lewis M. Drusin
Affiliation:
Department of Epidemiology, Department of Medicine, Cornell University Medical College, New York City, New York The New York Hospital, the Department of Public Health, Department of Medicine, Cornell University Medical College, New York City, New York Division of International Medicine and Infectious Diseases, Department of Medicine, Cornell University Medical College, New York City, New York
*
Department of Epidemiology, The New York Hospital-Cornell Medical Center, 525 East 68th St, HT-308, New York, NY 10021
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

To demonstrate the costs and benefits of vaccinating varicella-susceptible healthcare workers at a university hospital with live, attenuated varicella-zoster virus vaccine.

Design:

Retrospective review of employee medical records and data on the cost of special paid absence for susceptible healthcare workers after exposure to varicella or herpes zoster.

Setting:

A 988-bed tertiary-care university hospital.

Results:

In 1994, 224 hospital employees (3.4%) were susceptible to the varicella-zoster virus. There were 40 exposures to varicella and herpes zoster in that year, involving 29 of the susceptible employees. Nine (31%) of the exposed susceptibles became varicella immune by indirect fluorescent antibody testing subsequent to exposure. Seventeen (59%) have had multiple varicella exposures and special paid absences while employed by the hospital. In 1994, wages paid to healthcare workers while furloughed for the communicable period following varicella exposure totaled $38,463.93. An additional $24,748.74 was paid to replacement workers during that same time. Varicella vaccine to immunize all 224 susceptibles in 1994 would have cost $17,920. Absences due to varicella and herpes zoster exposure also result in disruptions to patient care.

Conclusions:

Varicella vaccination for varicella-susceptible healthcare workers at a university hospital would result in financial savings and improved patient care. We recommend that other institutions consider the costs and benefits of adopting a varicella immunization program for their susceptible employees.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 18 , Issue 6 , June 1997 , pp. 405 - 411
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1997

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Weller, TH, Witton, HM. The etiologic agents of varicella and herpes zoster. Serologic studies with the viruses as propagated in vitro. J Exp Med 1958;108:869–890.Google Scholar
2.Weller, TH. Varicella and herpes zoster: a perspective and overview. J Infect Dis 1992;166(suppl 1):1S–6S.Google Scholar
3. American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for the use of live attenuated varicella vaccine. Pediatrics 1995;95:791–796.Google Scholar
4.Gershon, AA. Varicella vaccine. Isr J Med Sci 1994;30:482–484.Google Scholar
5.Preblud, SR. Varicella: complications and costs. Pediatrics 1986;78(4, Pt 2):728–735.Google Scholar
6.Gershon, AA, Raker, R, Steinberg, S, Topf-Olstein, B, Drusin, LM. Antibody to varicella-zoster virus in parturient women and their offspring during the first year of life. Pediatrics 1976;58:692–696.Google Scholar
7.Gershon, AA, Steinberg, SP, LaRussa, P, et al. Immunization of healthy adults with live attenuated varicella vaccine. J Infect Dis 1988;158:132–137.Google Scholar
8.Kelley, PW, Petruccelli, BP, Stehr-Green, P, Erickson, RL, Mason, CJ. The susceptibility of young adult Americans to vaccine-preventable infections. A national serosurvey of US Army recruits. JAMA 1991;266:2724–2729.Google Scholar
9.Struewing, JP, Hyams, KC, Tueller, JE, Gray, GC. The risk of measles, mumps, and varicella among young adults: a serosurvey of US Navy and Marine Corps recruits. Am J Public Health 1993;83:1717–1720.Google Scholar
10.Ragozzino, MW, Melton, LJ III, Kurland, LT, Chu, CP, Perry, HO. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) 1982;61:310–316.Google Scholar
11.Gnann, JW, Whitley, RJ. Natural history and treatment of varicella-zoster in high-risk populations. J Hosp Infect 1991;18(suppl A):317–329.Google Scholar
12.Preblud, SR, Orenstein, WA, Bart, KJ. Varicella: clinical manifestations, epidemiology and health impact in children. Pediatr Infect Dis J 1984;3:505–509.Google Scholar
13.Guess, HA, Broughton, DD, Melton, LJ III, Kurland, LT. Population-based studies of varicella complications. Pediatrics 1986;78(4, Pt 2):723–727.Google Scholar
14.Preblud, SR. Age-specific risks of varicella complications. Pediatrics 1981;68:14–17.Google Scholar
15.Drwal-Klein, LA, O'Donovan, CA. Varicella in pediatric patients. Ann Pharmacother 1993;27:938–949.Google Scholar
16.Fleisher, G, Henry, W, McSorley, M, Arbeter, A, Plotkin, S. Life- threatening complications of varicella. Am J Dis Child 1981;135:896–899.Google Scholar
17.Lieu, TA, Black, SB, Rieser, N, Ray, P, Lewis, EM, Shinefield, HR. The cost of childhood chickenpox: parents' perspective. Pediatr Infect Dis J 1994;13:173–177.Google Scholar
18.Lieu, TA, Cochi, SL, Black, SB, et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA 1994;271:375–381.Google Scholar
19.Hyams, PJ, Stuewe, MC, Heitzer, V. Herpes zoster causing varicella (chickenpox) in hospital employees: cost of a casual attitude. Am J Infect Control 1984;12:2–5.Google Scholar
20.Krasinski, K, Holzman, RS, LaCouture, R, Florman, A. Hospital experience with varicella-zoster virus. Infect Control 1986;7:312–316.Google Scholar
21.Weber, DJ, Rutala, WA, Parham, C. Impact and costs of varicella prevention in a university hospital. Am J Public Health 1988;78:19–23.Google Scholar
22. Centers for Disease Control and Prevention. Licensure of varicella virus vaccine, live. MMWR 1995;44:264.Google Scholar
23.Nightingale, SL. From the Food and Drug Administration, Office of Health Affairs, FDA, Rockville, MD 20857, USA. Varicella Virus Vaccine Live licensed. JAMA 1995;273:1564.Google Scholar
24. Rules and Regulations of the State of New York. 10 NY Comp Code ch 5, §405.3.Google Scholar
25.Pugliese, G, Kroc, K, Metzler, S, Hardy, M, Hughes, L. OSHA's final bloodborne pathogens standard: a special briefing. Chicago, IL: American Hospital Association Division of Quality Resources. February 1992.Google Scholar
26.American Academy of Pediatrics. Varicella-zoster infections. In: Peter, G, ed. 1994 Red Book: Report of the Committee on Infectious Diseases. 23rd ed. Elk Grove Village, IL: American Academy of Pediatrics; 1994:510–517.Google Scholar
27.Professional Information Services Group. 1996 Drug Topics Red Book. Montvale, NJ: Medical Economics Co; 1996.Google Scholar
28.Gardner, P, Eickhoff, T, Poland, GA, Gross, P, Griffin, M, LaForce, M. Adult immunizations. Ann Intern Med 1996;12(1, pt 1):35–40.Google Scholar
29.Saiman, L, Crowley, K, Gershon, A. Nosocomial varicella infections. In: Abrutyn, E, Goldmann, DA, Scheckler, WE, eds. Infection Control Reference Service. Philadelphia, PA: WB Saunders. In press.Google Scholar
30.Gershon, AAA, LaRussa, P, Hardy, I, Steinberg, S, Silverstein, S. Varicella vaccine: the American experience. J Infect Dis 1992;166(suppl 1):63S–68S.Google Scholar
31.Gershon, AA. Varicella vaccine: still at the crossroads. Pediatrics 1992;90:144–148.Google Scholar
32.Centers for Disease Control and Prevention. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1996;45(no. RR-11): 1–36.Google Scholar
33.Alter, SJ, Hammond, JA, McVey, CJ, Meyers, MG. Susceptibility to varicella-zoster virus among adults at high risk for exposure. Infect Control 1986;7:448–451.Google Scholar
34.McKinney, WP, Horowitz, MM, Battiola, RJ. Susceptibility of hospital based health care personnel to varicella-zoster virus infections. Am J Infect Control 1989;17:26–30.Google Scholar
35.Murray, DL, Lynch, MA. Determination of immune status to measles, rubella, and varicella-zoster viruses among medical students: assessment of historical information. Am J Public Health 1988;78:836–838.Google Scholar
36.Nassar, NT, Touma, HC. Brief report: susceptibility of Filipino nurses to the varicella-zoster virus. Infect Control 1986;7:71–72.Google Scholar
37.Longfield, JN, Winn, RE, Gibson, RL, Juchau, SV, Hoffman, PV. Varicella outbreaks in army recruits from Puerto Rico. Varicella susceptibility in a population from the tropics. Arch Intern Med 1990;150:970–973.Google Scholar
38.Wreghitt, TG, Tedder, RS, Nagington, J, Ferns, RB. Antibody assays for varicella virus: comparison of competitive enzyme linked immunosorbent assay (ELISA), competitive radioimmunoassay (RIA), complement fixation, and indirect immunofluorescence assays (IFA). J Med Virol 1984;13:361–370.Google Scholar
39.LaRussa, P, Steinberg, S, Waithe, E, Hanna, B, Holzman, R. Comparison of five assays for antibody to varicella-zoster virus and the fluorescent-antibody-to-membrane-antigen test. J Clin Microbiol 1987;25:2059–2062.Google Scholar
40.Martins, TB, Jaskowski, TD, Schroder, C, Streeter, B, Hill, HR. Comparison of three commercially available assays for detection of varicella-zoster virus antibody. Clin Diagn Lab Immunol 1994;1:186–188.Google Scholar
41.Weibel, RE, Neff, BJ, Kuter, BJ, et al.Live attenuated varicella virus vaccine. Efficacy trial in healthy children. N Engl J Med 1984;310:1409–1415.Google Scholar
42.Tsolia, M, Gershon, AA, Steinberg, SP, Gelb, L. Live attenuated varicella vaccine: evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus. J Pediatr 1990;116:184–189.Google Scholar
43.Diaz, PS, Au, D, Smith, S, et al. Lack of transmission of the live attenuated varicella vaccine virus to immunocompromised children after immunization of their siblings. Pediatrics 1991;87:166–170.Google Scholar
44.Gershon, AA. Varicella vaccine: its past, present, and future. Pediatr Infect Dis J 1995;14:742–744.Google Scholar